Dyslipidemias: Pathophysiology, Evaluation and Management (Hardcover) (ISBN-13: 9781607614234)

Chapter 1. Lipoprotein Physiology

Chapter 2. Epidemiology of Blood Lipids and Lipoproteins

Chapter 3. Lipoprotein(a)

Chapter 4. Lipoproteins and Cardiovascular Disease Risk

Chapter 5. Detection and Treatment of Children and Adolescents with Dyslipidemia

Chapter 6. Type 2 Diabetes Mellitus and Dyslipidemia

Chapter 7. Type 1 Diabetes Mellitus and Dyslipidemia

Chapter 8. Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome

Chapter 9. Dyslipidemia in HIV-infected Patients

Chapter 10. Monogenic Hypercholesterolemia

Chapter 11. Primary Hypertriglyceridemia

Chapter 12. Genetic Disorders of HDL Metabolism

Chapter 13. Sitosterolemia and Other Rare Sterol Disorders

Chapter 14. Genetic Abetalipoproteinemia & Hypobetalipoproteinemia

Chapter 15. Drug-induced Dyslipidemia

Chapter 16. Lipodystrophies and Dyslipidemias

Chapter 17. Novel Genes for Dyslipidemias: Genome-Wide Association Studies

Chapter 18. Perspectives on Cholesterol Guidelines

Chapter 19. Nutrition and Coronary Heart Disease Prevention

Chapter 20. Phytosterol Therapy

Chapter 21. N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease

Chapter 22. Polyphenols for Cholesterol Management

Chapter 23 - Dietary Supplements for Cholesterol Management

Chapter 24. Statins: Risk-Benefits and Role in Treating Dyslipidemias

Chapter 25. Fibrates: Risk-Benefits and Role in Treating Dyslipidemias

Chapter 26. Niacin: Risk-Benefits and Role in Treating Dyslipidemias

Chapter 27. Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias

Chapter 28. Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias

Chapter 29. Low Density Lipoprotein (LDL) Apheresis

Chapter 30. Novel Lipid Lowering Agents